{
    "4 25 2025": {
        "importantArticles": [
            {
                "headline": "Both U.S.-based Summit Therapeutics (NASDAQ: SMMT) and BioNTech (NASDAQ: BNTX) were down significantly, plunging 36.1% and 15.4%, respectively, in Friday's trading.  The severe moves were likely related to a Chinese rival in the PD-1/VEGF bispecific antibody area, Akeso (OTC: AKES.F), receiving FDA approval for a cancer drug that utilizes similar technology, as well as an additional approval in China.  As a result, Akeso shares were up 11.7% on Friday.",
                "publication_date": "2025-04-25T00:00:00.000Z",
                "sentiment": "Positive",
                "sentimentScore": "0.5994",
                "source": "Motley Fool",
                "ticker": "SMMT",
                "title": "Why Biotech Stars Summit Therapeutics and BioNTech Plunged, Even as This Chinese Rival Surged Today",
                "url": "https://finance.yahoo.com/news/why-biotech-stars-summit-therapeutics-210519433.html"
            },
            {
                "headline": "MIAMI, April 25, 2025--Summit Therapeutics Inc. (NASDAQ: SMMT) (\"Summit,\" \"we,\" or the \"Company\") today noted that Akeso, Inc. (Akeso, HKEX Code: 9926.HK) announced that ivonescimab was approved by the Chinese Health Authorities, the National Medical Products Administration (NMPA), for a second indication based on the results of the Phase III clinical trial, HARMONi-2 or AK112-303. HARMONi-2 evaluated monotherapy ivonescimab against monotherapy pembrolizumab in patients with locally advanced or",
                "publication_date": "2025-04-25T00:00:00.000Z",
                "sentiment": "Positive",
                "sentimentScore": "0.5859",
                "source": "Business Wire",
                "ticker": "SMMT",
                "title": "Interim Overall Survival Analysis Requested from Chinese Health Authorities Shows a Clinically Meaningful, Positive Trend Favoring Ivonescimab Compared to Pembrolizumab in PD-L1 Positive Advanced NSCLC from HARMONi-2 Study Conducted by Akeso in China",
                "url": "https://finance.yahoo.com/news/interim-overall-survival-analysis-requested-185000973.html"
            },
            {
                "headline": "MIAMI, April 25, 2025--Summit Therapeutics Inc. (NASDAQ: SMMT) (\"Summit,\" \"we,\" or the \"Company\") today noted that Akeso, Inc. (Akeso, HKEX Code: 9926.HK) announced that ivonescimab was approved by the Chinese Health Authorities, the National Medical Products Administration (NMPA), for a second indication based on the results of the Phase III clinical trial, HARMONi-2 or AK112-303. HARMONi-2 evaluated monotherapy ivonescimab against monotherapy pembrolizumab in patients with locally advanced or",
                "publication_date": "2025-04-25T00:00:00.000Z",
                "sentiment": "Positive",
                "sentimentScore": "0.5859",
                "source": "Business Wire",
                "ticker": "SMMT",
                "title": "Interim Overall Survival Analysis Requested from Chinese Health Authorities Shows a Clinically Meaningful, Positive Trend Favoring Ivonescimab Compared to Pembrolizumab in PD-L1 Positive Advanced NSCLC from HARMONi-2 Study Conducted by Akeso in China",
                "url": "https://finance.yahoo.com/news/interim-overall-survival-analysis-requested-185000973.html"
            },
            {
                "headline": "Both U.S.-based Summit Therapeutics (NASDAQ: SMMT) and BioNTech (NASDAQ: BNTX) were down significantly, plunging 36.1% and 15.4%, respectively, in Friday's trading.  The severe moves were likely related to a Chinese rival in the PD-1/VEGF bispecific antibody area, Akeso (OTC: AKES.F), receiving FDA approval for a cancer drug that utilizes similar technology, as well as an additional approval in China.  As a result, Akeso shares were up 11.7% on Friday.",
                "publication_date": "2025-04-25T00:00:00.000Z",
                "sentiment": "Positive",
                "sentimentScore": "0.5994",
                "source": "Motley Fool",
                "ticker": "SMMT",
                "title": "Why Biotech Stars Summit Therapeutics and BioNTech Plunged, Even as This Chinese Rival Surged Today",
                "url": "https://finance.yahoo.com/news/why-biotech-stars-summit-therapeutics-210519433.html"
            }
        ],
        "avgScore": 0.59265,
        "pctChange": -0.31469044969864
    },
    "4 24 2025": {
        "importantArticles": [
            {
                "headline": "MIAMI, April 24, 2025--Summit Therapeutics Inc. (NASDAQ: SMMT) (\"Summit,\" \"we,\" or the \"Company\") will host an earnings call to announce its first quarter 2025 financial results and provide an operational update for the Company on Thursday, May 1, 2025, after the market closes.",
                "publication_date": "2025-04-24T00:00:00.000Z",
                "sentiment": "Neutral",
                "sentimentScore": "0.0",
                "source": "Business Wire",
                "ticker": "SMMT",
                "title": "Summit Therapeutics to Host First Quarter 2025 Financial Results & Operational Progress Call on May 1, 2025",
                "url": "https://finance.yahoo.com/news/summit-therapeutics-host-first-quarter-201500118.html"
            },
            {
                "headline": "Akeso and Summit's drug previously beat Keytruda in a separate Phase III study, extending PFS by five months.",
                "publication_date": "2025-04-24T00:00:00.000Z",
                "sentiment": "Neutral",
                "sentimentScore": "0.0",
                "source": "Clinical Trials Arena",
                "ticker": "SMMT",
                "title": "Akeso and Summit notch another Phase III win with their Keytruda competitor",
                "url": "https://finance.yahoo.com/news/akeso-summit-notch-another-phase-120019766.html"
            },
            {
                "headline": "Akeso and Summit's drug previously beat Keytruda in a separate Phase III study, extending PFS by five months.",
                "publication_date": "2025-04-24T00:00:00.000Z",
                "sentiment": "Neutral",
                "sentimentScore": "0.0",
                "source": "Clinical Trials Arena",
                "ticker": "SMMT",
                "title": "Akeso and Summit notch another Phase III win with their Keytruda competitor",
                "url": "https://finance.yahoo.com/news/akeso-summit-notch-another-phase-120019766.html"
            },
            {
                "headline": "MIAMI, April 24, 2025--Summit Therapeutics Inc. (NASDAQ: SMMT) (\"Summit,\" \"we,\" or the \"Company\") will host an earnings call to announce its first quarter 2025 financial results and provide an operational update for the Company on Thursday, May 1, 2025, after the market closes.",
                "publication_date": "2025-04-24T00:00:00.000Z",
                "sentiment": "Neutral",
                "sentimentScore": "0.0",
                "source": "Business Wire",
                "ticker": "SMMT",
                "title": "Summit Therapeutics to Host First Quarter 2025 Financial Results & Operational Progress Call on May 1, 2025",
                "url": "https://finance.yahoo.com/news/summit-therapeutics-host-first-quarter-201500118.html"
            }
        ],
        "avgScore": 0.0,
        "pctChange": -0.3606267121312048
    },
    "4 23 2025": {
        "importantArticles": [
            {
                "headline": "Nobody has more information about a company than its insiders, especially its executive management team.  On April 8, Summit Therapeutics' co-CEOs, Robert Duggan and Maky Zanganeh, each exercised warrants, financial instruments that grant their holders the right (but not the obligation) to acquire a company's shares at a predetermined price before a particular date.  Do Summit Therapeutics' prospects -- beyond this recent development -- justify investing in the stock today?",
                "publication_date": "2025-04-23T00:00:00.000Z",
                "sentiment": "Positive",
                "sentimentScore": "0.7096",
                "source": "Motley Fool",
                "ticker": "SMMT",
                "title": "This Company's Co-CEOs Just Bought More Shares. Should You?",
                "url": "https://finance.yahoo.com/news/companys-co-ceos-just-bought-094500957.html"
            },
            {
                "headline": "MIAMI, April 23, 2025--Summit Therapeutics Inc. (NASDAQ: SMMT) (\"Summit,\" \"we,\" or the \"Company\") today noted that Akeso, Inc. (Akeso, HKEX Code: 9926.HK) announced that the Phase III clinical trial, HARMONi-6 or AK112-306, met its primary endpoint of progression-free survival (PFS). HARMONi-6 is evaluating ivonescimab in combination with platinum-based chemotherapy compared with tislelizumab, a PD-1 inhibitor, in combination with platinum-based chemotherapy in patients with locally advanced or",
                "publication_date": "2025-04-23T00:00:00.000Z",
                "sentiment": "Positive",
                "sentimentScore": "0.1779",
                "source": "Business Wire",
                "ticker": "SMMT",
                "title": "Ivonescimab in Combination with Chemotherapy Achieves Statistically Significant Superiority in PFS vs. Tislelizumab (PD-1 Inhibitor) Plus Chemotherapy in 1L Treatment of Patients with Squamous NSCLC in HARMONi-6 Study Conducted by Akeso in China",
                "url": "https://finance.yahoo.com/news/ivonescimab-combination-chemotherapy-achieves-statistically-101500586.html"
            },
            {
                "headline": "BioNTech stock rocketed Wednesday after rival Summit Therapeutics unveiled promising results for a novel approach to lung cancer treatment.",
                "publication_date": "2025-04-23T00:00:00.000Z",
                "sentiment": "Negative",
                "sentimentScore": "-0.1027",
                "source": "Investor's Business Daily",
                "ticker": "SMMT",
                "title": "BioNTech Surges On Summit's Coattails. But Can They Take On Merck?",
                "url": "https://finance.yahoo.com/m/a6583d72-b7a0-347a-829e-9cdb842158e1/biontech-surges-on-summit-s.html"
            },
            {
                "headline": "Summit Therapeutics Inc.'s (NASDAQ:SMMT) partner, Akeso, Inc., released topline data from the Phase 3 HARMONi-6/K112-306 trial on Wednesday. The trial is evaluating ivonescimab in combination with platinum-based chemotherapy compared with tislelizumab, an anti-PD-1 antibody, in combination with platinum-based chemotherapy in patients with locally advanced or metastatic squamous non-small cell lung cancer (NSCLC), irrespective of PD-L1 expression. HARMONi-6 is a study conducted in China sponsored",
                "publication_date": "2025-04-23T00:00:00.000Z",
                "sentiment": "Negative",
                "sentimentScore": "-0.5267",
                "source": "Benzinga",
                "ticker": "SMMT",
                "title": "Why Is Summit Therapeutics Stock Soaring On Wednesday?",
                "url": "https://finance.yahoo.com/news/why-summit-therapeutics-stock-soaring-194743694.html"
            },
            {
                "headline": "Shares of lung cancer biotech Summit Therapeutics (NASDAQ: SMMT) rocketed 14.7% on Wednesday as of 1:45 p.m. ET.  Summit disclosed some preliminary results of its HARMONi-6 trial, conducted in partnership with Akeso.  In the trial, Summit's antibody drug ivonescimab was administered along with platinum-based chemotherapy against the current standard of care, tislelizumab, which is made by BeiGene (NASDAQ: BGNE), in patients with locally advanced or metastatic squamous non-small cell lung cancer (NSCLC).",
                "publication_date": "2025-04-23T00:00:00.000Z",
                "sentiment": "Negative",
                "sentimentScore": "-0.5267",
                "source": "Motley Fool",
                "ticker": "SMMT",
                "title": "Why Summit Therapeutics Rocketed Double-Digits Today",
                "url": "https://finance.yahoo.com/news/why-summit-therapeutics-rocketed-double-200500961.html"
            },
            {
                "headline": "We recently published a list of These 10 Firms Topped Wednesday\u2019s Trading. In this article, we are going to take a look at where Summit Therapeutics Inc. (NASDAQ:SMMT) stands against other firms that topped Wednesday\u2019s trading. Wall Street\u2019s major indices rebounded anew on Wednesday as worries about tariff policies and the Federal Reserve\u2019s independence tapered [\u2026]",
                "publication_date": "2025-04-23T00:00:00.000Z",
                "sentiment": "Negative",
                "sentimentScore": "-0.4215",
                "source": "Insider Monkey",
                "ticker": "SMMT",
                "title": "Why Summit Therapeutics Inc. (SMMT) Went Up On Wednesday",
                "url": "https://finance.yahoo.com/news/why-summit-therapeutics-inc-smmt-221356671.html"
            }
        ],
        "avgScore": -0.11501666666666666,
        "pctChange": 0.10442375168536036
    },
    "4 15 2025": {
        "importantArticles": [
            {
                "headline": "We recently published a list of Biotech Stocks Dominate Monday\u2019s Top 10 Gainers. In this article, we are going to take a look at where Summit Therapeutics Inc. (NASDAQ:SMMT) stands against other biotech stocks that dominate Monday\u2019s top gainers. The stock market kicked off the shortened trading week on a positive note, with Wall Street\u2019s [\u2026]",
                "publication_date": "2025-04-15T00:00:00.000Z",
                "sentiment": "Positive",
                "sentimentScore": "0.6369",
                "source": "Insider Monkey",
                "ticker": "SMMT",
                "title": "Why Summit Therapeutics Inc. (SMMT) Skyrocketed On Monday?",
                "url": "https://finance.yahoo.com/news/why-summit-therapeutics-inc-smmt-044010439.html"
            },
            {
                "headline": "We recently published a list of Biotech Stocks Dominate Monday\u2019s Top 10 Gainers. In this article, we are going to take a look at where Summit Therapeutics Inc. (NASDAQ:SMMT) stands against other biotech stocks that dominate Monday\u2019s top gainers. The stock market kicked off the shortened trading week on a positive note, with Wall Street\u2019s [\u2026]",
                "publication_date": "2025-04-15T00:00:00.000Z",
                "sentiment": "Positive",
                "sentimentScore": "0.6369",
                "source": "Insider Monkey",
                "ticker": "SMMT",
                "title": "Why Summit Therapeutics Inc. (SMMT) Skyrocketed On Monday?",
                "url": "https://finance.yahoo.com/news/why-summit-therapeutics-inc-smmt-044010439.html"
            }
        ],
        "avgScore": 0.6369,
        "pctChange": -0.06376935615984883
    },
    "4 14 2025": {
        "importantArticles": [
            {
                "headline": "Summit Therapeutics (NasdaqGM:SMMT) recently experienced an executive shakeup with the appointment of Robert LaCaze as Chief Commercial Officer, which could have influenced its stock price increase of nearly 40% over the last quarter. LaCaze brings substantial experience in oncology, possibly strengthening market confidence in the company's growth initiatives. Additionally, the firm's collaboration with Pfizer to evaluate ivonescimab in combination with Pfizer's ADCs may have bolstered its...",
                "publication_date": "2025-04-14T00:00:00.000Z",
                "sentiment": "Positive",
                "sentimentScore": "0.891",
                "source": "Simply Wall St.",
                "ticker": "SMMT",
                "title": "Summit Therapeutics (NasdaqGM:SMMT) Welcomes Robert LaCaze As New Chief Commercial Officer",
                "url": "https://finance.yahoo.com/news/summit-therapeutics-nasdaqgm-smmt-welcomes-173132253.html"
            },
            {
                "headline": "The surge in SMMT's share price comes after some established investment firms maintain their positive outlook on the company, citing optimism around its lead pipeline drug.",
                "publication_date": "2025-04-14T00:00:00.000Z",
                "sentiment": "Positive",
                "sentimentScore": "0.8519",
                "source": "Zacks",
                "ticker": "SMMT",
                "title": "Here's Why Summit Therapeutics Stock Soared 15% on Friday",
                "url": "https://finance.yahoo.com/news/heres-why-summit-therapeutics-stock-095700433.html"
            },
            {
                "headline": "The surge in SMMT's share price comes after some established investment firms maintain their positive outlook on the company, citing optimism around its lead pipeline drug.",
                "publication_date": "2025-04-14T00:00:00.000Z",
                "sentiment": "Positive",
                "sentimentScore": "0.8519",
                "source": "Zacks",
                "ticker": "SMMT",
                "title": "Here's Why Summit Therapeutics Stock Soared 15% on Friday",
                "url": "https://finance.yahoo.com/news/heres-why-summit-therapeutics-stock-095700433.html"
            },
            {
                "headline": "Summit Therapeutics (NasdaqGM:SMMT) recently experienced an executive shakeup with the appointment of Robert LaCaze as Chief Commercial Officer, which could have influenced its stock price increase of nearly 40% over the last quarter. LaCaze brings substantial experience in oncology, possibly strengthening market confidence in the company's growth initiatives. Additionally, the firm's collaboration with Pfizer to evaluate ivonescimab in combination with Pfizer's ADCs may have bolstered its...",
                "publication_date": "2025-04-14T00:00:00.000Z",
                "sentiment": "Positive",
                "sentimentScore": "0.891",
                "source": "Simply Wall St.",
                "ticker": "SMMT",
                "title": "Summit Therapeutics (NasdaqGM:SMMT) Welcomes Robert LaCaze As New Chief Commercial Officer",
                "url": "https://finance.yahoo.com/news/summit-therapeutics-nasdaqgm-smmt-welcomes-173132253.html"
            }
        ],
        "avgScore": 0.8714500000000001,
        "pctChange": -0.05778792078188887
    },
    "4 11 2025": {
        "importantArticles": [
            {
                "headline": "The Survival read-out on the Summit Therapeutics (SMMT)\u2019 HARMONi-2 study is one of the most anticipated biotech datapoints this year, and Truist tells investors in a research note that its biostatistics expert consultation gives the firm confidence that this study could beat expectations, and may even show statistical significance. The firm believes that the consensus \u201chome-run scenario\u201d will drive up Summit shares materially if it plays out. Truist has a Buy rating and $35 price target on the s",
                "publication_date": "2025-04-11T00:00:00.000Z",
                "sentiment": "Positive",
                "sentimentScore": "0.8225",
                "source": "TipRanks",
                "ticker": "SMMT",
                "title": "Expert says Summit\u2019s HARMONi-2 study could beat expectations, says Truist",
                "url": "https://finance.yahoo.com/news/expert-says-summit-harmoni-2-161010630.html"
            },
            {
                "headline": "We recently published a list of 10 Firms Buck Thursday\u2019s Market Bloodbath. In this article, we are going to take a look at where Summit Therapeutics Inc. (NASDAQ:SMMT) stands against other Thursday\u2019s best performers. Investors sold off positions on Thursday, sending the stock market tumbling anew following President Donald Trump\u2019s announcement that he had actually [\u2026]",
                "publication_date": "2025-04-11T00:00:00.000Z",
                "sentiment": "Positive",
                "sentimentScore": "0.6369",
                "source": "Insider Monkey",
                "ticker": "SMMT",
                "title": "Why Summit Therapeutics Inc. (SMMT) Went Up On Thursday?",
                "url": "https://finance.yahoo.com/news/why-summit-therapeutics-inc-smmt-104625944.html"
            },
            {
                "headline": "Cantor Fitzgerald views Bob Duggan\u2019s, Summit Therapeutics (SMMT) co-CEO and Chairman, stock option exercise \u201cquite unusual\u201d and \u201cquite bullish\u201d for the shares. Duggan\u2019 exercised warrants to purchase 4M shares of Summit at $1.58 approximately four years before their expiration, the analyst tells investors in a research note. Cantor has an Overweight rating on Summit Therapeutics. The stock in midday trading is up 9%, or $1.66, to $19.89. Published first on TheFly \u2013 the ultimate source for real-ti",
                "publication_date": "2025-04-11T00:00:00.000Z",
                "sentiment": "Positive",
                "sentimentScore": "0.2263",
                "source": "TipRanks",
                "ticker": "SMMT",
                "title": "Summit co-CEO option exercise \u2018quite bullish,\u2019 says Cantor Fitzgerald",
                "url": "https://finance.yahoo.com/news/summit-co-ceo-option-exercise-161524830.html"
            },
            {
                "headline": "Cantor Fitzgerald views Bob Duggan\u2019s, Summit Therapeutics (SMMT) co-CEO and Chairman, stock option exercise \u201cquite unusual\u201d and \u201cquite bullish\u201d for the shares. Duggan\u2019 exercised warrants to purchase 4M shares of Summit at $1.58 approximately four years before their expiration, the analyst tells investors in a research note. Cantor has an Overweight rating on Summit Therapeutics. The stock in midday trading is up 9%, or $1.66, to $19.89. Published first on TheFly \u2013 the ultimate source for real-ti",
                "publication_date": "2025-04-11T00:00:00.000Z",
                "sentiment": "Positive",
                "sentimentScore": "0.2263",
                "source": "TipRanks",
                "ticker": "SMMT",
                "title": "Summit co-CEO option exercise \u2018quite bullish,\u2019 says Cantor Fitzgerald",
                "url": "https://finance.yahoo.com/news/summit-co-ceo-option-exercise-161524830.html"
            },
            {
                "headline": "We recently published a list of 10 Firms Buck Thursday\u2019s Market Bloodbath. In this article, we are going to take a look at where Summit Therapeutics Inc. (NASDAQ:SMMT) stands against other Thursday\u2019s best performers. Investors sold off positions on Thursday, sending the stock market tumbling anew following President Donald Trump\u2019s announcement that he had actually [\u2026]",
                "publication_date": "2025-04-11T00:00:00.000Z",
                "sentiment": "Positive",
                "sentimentScore": "0.6369",
                "source": "Insider Monkey",
                "ticker": "SMMT",
                "title": "Why Summit Therapeutics Inc. (SMMT) Went Up On Thursday?",
                "url": "https://finance.yahoo.com/news/why-summit-therapeutics-inc-smmt-104625944.html"
            },
            {
                "headline": "The Survival read-out on the Summit Therapeutics (SMMT)\u2019 HARMONi-2 study is one of the most anticipated biotech datapoints this year, and Truist tells investors in a research note that its biostatistics expert consultation gives the firm confidence that this study could beat expectations, and may even show statistical significance. The firm believes that the consensus \u201chome-run scenario\u201d will drive up Summit shares materially if it plays out. Truist has a Buy rating and $35 price target on the s",
                "publication_date": "2025-04-11T00:00:00.000Z",
                "sentiment": "Positive",
                "sentimentScore": "0.8225",
                "source": "TipRanks",
                "ticker": "SMMT",
                "title": "Expert says Summit\u2019s HARMONi-2 study could beat expectations, says Truist",
                "url": "https://finance.yahoo.com/news/expert-says-summit-harmoni-2-161010630.html"
            }
        ],
        "avgScore": 0.5619,
        "pctChange": 0.12435453606329312
    },
    "4 10 2025": {
        "importantArticles": [
            {
                "headline": "Shares of lung cancer-focused biotech Summit Therapeutics (NASDAQ: SMMT) rallied 16.6% at its highs of the day before settling into a 10.4% gain on Thursday as of 3:54 p.m. EDT, even though the broader markets were down significantly on the day at that time, including the SPDR S&P Biotech ETF (NYSEMKT: XBI), which was down 4.4%.  The interesting news for Summit was that two insiders exercised warrants on Summit's stock yesterday, which most interpreted as being highly bullish.  What is notable is that the Co-CEOs exercised these warrants, forcing them to buy $6.3 million worth of shares, about four and a half years before the warrants' expiration in December of 2029.",
                "publication_date": "2025-04-10T00:00:00.000Z",
                "sentiment": "Positive",
                "sentimentScore": "0.886",
                "source": "Motley Fool",
                "ticker": "SMMT",
                "title": "Why Summit Therapeutics Rallied Double Digits Today on Another Down day for the Markets",
                "url": "https://finance.yahoo.com/news/why-summit-therapeutics-rallied-double-203600707.html"
            },
            {
                "headline": "Shares of lung cancer-focused biotech Summit Therapeutics (NASDAQ: SMMT) rallied 16.6% at its highs of the day before settling into a 10.4% gain on Thursday as of 3:54 p.m. EDT, even though the broader markets were down significantly on the day at that time, including the SPDR S&P Biotech ETF (NYSEMKT: XBI), which was down 4.4%.  The interesting news for Summit was that two insiders exercised warrants on Summit's stock yesterday, which most interpreted as being highly bullish.  What is notable is that the Co-CEOs exercised these warrants, forcing them to buy $6.3 million worth of shares, about four and a half years before the warrants' expiration in December of 2029.",
                "publication_date": "2025-04-10T00:00:00.000Z",
                "sentiment": "Positive",
                "sentimentScore": "0.886",
                "source": "Motley Fool",
                "ticker": "SMMT",
                "title": "Why Summit Therapeutics Rallied Double Digits Today on Another Down day for the Markets",
                "url": "https://finance.yahoo.com/news/why-summit-therapeutics-rallied-double-203600707.html"
            }
        ],
        "avgScore": 0.886,
        "pctChange": 0.1533498864062645
    },
    "4 4 2025": {
        "importantArticles": [
            {
                "headline": "MIAMI, April 04, 2025--Summit Therapeutics Inc. (NASDAQ: SMMT) (\"Summit,\" \"we,\" or the \"Company\") today announced the grant of inducement awards of options to purchase a collective total of up to 176,915 shares of common stock. Awards were made to ten (10) new employees of the Company. The awards were granted as an inducement material to the new employees becoming employees of the Company in accordance with Nasdaq Listing Rule 5635(c)(4) and have been approved by the Company\u2019s Compensation Commi",
                "publication_date": "2025-04-04T00:00:00.000Z",
                "sentiment": "Positive",
                "sentimentScore": "0.9477",
                "source": "Business Wire",
                "ticker": "SMMT",
                "title": "Summit Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)",
                "url": "https://finance.yahoo.com/news/summit-therapeutics-reports-inducement-grants-201500285.html"
            },
            {
                "headline": "MIAMI, April 04, 2025--Summit Therapeutics Inc. (NASDAQ: SMMT) (\"Summit,\" \"we,\" or the \"Company\") today announced the grant of inducement awards of options to purchase a collective total of up to 176,915 shares of common stock. Awards were made to ten (10) new employees of the Company. The awards were granted as an inducement material to the new employees becoming employees of the Company in accordance with Nasdaq Listing Rule 5635(c)(4) and have been approved by the Company\u2019s Compensation Commi",
                "publication_date": "2025-04-04T00:00:00.000Z",
                "sentiment": "Positive",
                "sentimentScore": "0.9477",
                "source": "Business Wire",
                "ticker": "SMMT",
                "title": "Summit Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)",
                "url": "https://finance.yahoo.com/news/summit-therapeutics-reports-inducement-grants-201500285.html"
            }
        ],
        "avgScore": 0.9477,
        "pctChange": -0.0023042001221757836
    },
    "4 3 2025": {
        "importantArticles": [
            {
                "headline": "Is the excitement surrounding chipmaker Nvidia fading?  Whether that's due to its high valuation, concerns about the economy, tariffs, or the possibility of a slowdown in tech spending on the horizon, investors don't appear as eager to own the stock anymore.  What may surprise you is that even over the past 12 months, Nvidia stock has risen by just 20% -- a solid return but not the type investors may have been expecting from the chipmaker, given the growth opportunities in artificial intelligence (AI).",
                "publication_date": "2025-04-03T00:00:00.000Z",
                "sentiment": "Positive",
                "sentimentScore": "0.9238",
                "source": "Motley Fool",
                "ticker": "SMMT",
                "title": "3 Growth Stocks That Have Dwarfed Nvidia's Returns Over the Past 12 Months",
                "url": "https://finance.yahoo.com/news/3-growth-stocks-dwarfed-nvidias-134500205.html"
            },
            {
                "headline": "Esperion Therapeutics (ESPR) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.",
                "publication_date": "2025-04-03T00:00:00.000Z",
                "sentiment": "Neutral",
                "sentimentScore": "0.0",
                "source": "Zacks",
                "ticker": "SMMT",
                "title": "Esperion Therapeutics (ESPR) Down 15.8% Since Last Earnings Report: Can It Rebound?",
                "url": "https://finance.yahoo.com/news/esperion-therapeutics-espr-down-15-153007148.html"
            },
            {
                "headline": "Esperion Therapeutics (ESPR) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.",
                "publication_date": "2025-04-03T00:00:00.000Z",
                "sentiment": "Neutral",
                "sentimentScore": "0.0",
                "source": "Zacks",
                "ticker": "SMMT",
                "title": "Esperion Therapeutics (ESPR) Down 15.8% Since Last Earnings Report: Can It Rebound?",
                "url": "https://finance.yahoo.com/news/esperion-therapeutics-espr-down-15-153007148.html"
            },
            {
                "headline": "Is the excitement surrounding chipmaker Nvidia fading?  Whether that's due to its high valuation, concerns about the economy, tariffs, or the possibility of a slowdown in tech spending on the horizon, investors don't appear as eager to own the stock anymore.  What may surprise you is that even over the past 12 months, Nvidia stock has risen by just 20% -- a solid return but not the type investors may have been expecting from the chipmaker, given the growth opportunities in artificial intelligence (AI).",
                "publication_date": "2025-04-03T00:00:00.000Z",
                "sentiment": "Positive",
                "sentimentScore": "0.9238",
                "source": "Motley Fool",
                "ticker": "SMMT",
                "title": "3 Growth Stocks That Have Dwarfed Nvidia's Returns Over the Past 12 Months",
                "url": "https://finance.yahoo.com/news/3-growth-stocks-dwarfed-nvidias-134500205.html"
            }
        ],
        "avgScore": 0.4619,
        "pctChange": -0.08196717343034082
    },
    "3 31 2025": {
        "importantArticles": [
            {
                "headline": "Building a retirement portfolio of $1 million or more is within reach for many Americans.  AbbVie (NYSE: ABBV) is a great example of a company that has proved such a capability.  A few years ago, some wondered what would happen to AbbVie after key patents expired for Humira, the company's top-selling drug.",
                "publication_date": "2025-03-31T00:00:00.000Z",
                "sentiment": "Positive",
                "sentimentScore": "0.6666",
                "source": "Motley Fool",
                "ticker": "SMMT",
                "title": "Want $1 Million in Retirement? 3 Stocks to Buy Now and Hold for Decades.",
                "url": "https://finance.yahoo.com/news/want-1-million-retirement-3-085300048.html"
            },
            {
                "headline": "All three companies are early-stage biotechnology companies working on next-generation therapeutics with advanced technologies.  Over the weekend, Dr. Peter Marks, who headed the FDA's Center for Biologics Evaluation and Research, as well as its vaccine division, resigned in protest.",
                "publication_date": "2025-03-31T00:00:00.000Z",
                "sentiment": "Neutral",
                "sentimentScore": "0.0258",
                "source": "Motley Fool",
                "ticker": "SMMT",
                "title": "Why Biotech Stocks Like Recursion Pharmaceuticals, CRISPR Therapeutics, and Summit Therapeutics Plunged Today",
                "url": "https://finance.yahoo.com/news/why-biotech-stocks-recursion-pharmaceuticals-192505216.html"
            },
            {
                "headline": "All three companies are early-stage biotechnology companies working on next-generation therapeutics with advanced technologies.  Over the weekend, Dr. Peter Marks, who headed the FDA's Center for Biologics Evaluation and Research, as well as its vaccine division, resigned in protest.",
                "publication_date": "2025-03-31T00:00:00.000Z",
                "sentiment": "Neutral",
                "sentimentScore": "0.0258",
                "source": "Motley Fool",
                "ticker": "SMMT",
                "title": "Why Biotech Stocks Like Recursion Pharmaceuticals, CRISPR Therapeutics, and Summit Therapeutics Plunged Today",
                "url": "https://finance.yahoo.com/news/why-biotech-stocks-recursion-pharmaceuticals-192505216.html"
            },
            {
                "headline": "Building a retirement portfolio of $1 million or more is within reach for many Americans.  AbbVie (NYSE: ABBV) is a great example of a company that has proved such a capability.  A few years ago, some wondered what would happen to AbbVie after key patents expired for Humira, the company's top-selling drug.",
                "publication_date": "2025-03-31T00:00:00.000Z",
                "sentiment": "Positive",
                "sentimentScore": "0.6666",
                "source": "Motley Fool",
                "ticker": "SMMT",
                "title": "Want $1 Million in Retirement? 3 Stocks to Buy Now and Hold for Decades.",
                "url": "https://finance.yahoo.com/news/want-1-million-retirement-3-085300048.html"
            }
        ],
        "avgScore": 0.3462,
        "pctChange": -0.02540184837795283
    },
    "3 28 2025": {
        "importantArticles": [
            {
                "headline": "Corcept (CORT) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.",
                "publication_date": "2025-03-28T00:00:00.000Z",
                "sentiment": "Neutral",
                "sentimentScore": "0.0",
                "source": "Zacks",
                "ticker": "SMMT",
                "title": "Why Is Corcept (CORT) Down 5.3% Since Last Earnings Report?",
                "url": "https://finance.yahoo.com/news/why-corcept-cort-down-5-153042433.html"
            },
            {
                "headline": "Corcept (CORT) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.",
                "publication_date": "2025-03-28T00:00:00.000Z",
                "sentiment": "Neutral",
                "sentimentScore": "0.0",
                "source": "Zacks",
                "ticker": "SMMT",
                "title": "Why Is Corcept (CORT) Down 5.3% Since Last Earnings Report?",
                "url": "https://finance.yahoo.com/news/why-corcept-cort-down-5-153042433.html"
            }
        ],
        "avgScore": 0.0,
        "pctChange": -0.05068891706525122
    },
    "3 26 2025": {
        "importantArticles": [
            {
                "headline": "In contrast to other titles that fell notably, Summit more or less kept pace with the S&P 500 (SNPINDEX: ^GSPC), managing to dip by a relatively modest 2.25% in price.  Well before market open, Citigroup pundit Yigal Nochomovitz changed his recommendation on Summit's shares to buy from neutral.  This is a rather promising cancer drug Summit has licensed from Chinese peer Akeso.",
                "publication_date": "2025-03-26T00:00:00.000Z",
                "sentiment": "Positive",
                "sentimentScore": "0.1531",
                "source": "Motley Fool",
                "ticker": "SMMT",
                "title": "Why Summit Therapeutics Stock Slipped Today",
                "url": "https://finance.yahoo.com/news/why-summit-therapeutics-stock-slipped-212125917.html"
            },
            {
                "headline": "In contrast to other titles that fell notably, Summit more or less kept pace with the S&P 500 (SNPINDEX: ^GSPC), managing to dip by a relatively modest 2.25% in price.  Well before market open, Citigroup pundit Yigal Nochomovitz changed his recommendation on Summit's shares to buy from neutral.  This is a rather promising cancer drug Summit has licensed from Chinese peer Akeso.",
                "publication_date": "2025-03-26T00:00:00.000Z",
                "sentiment": "Positive",
                "sentimentScore": "0.1531",
                "source": "Motley Fool",
                "ticker": "SMMT",
                "title": "Why Summit Therapeutics Stock Slipped Today",
                "url": "https://finance.yahoo.com/news/why-summit-therapeutics-stock-slipped-212125917.html"
            }
        ],
        "avgScore": 0.1531,
        "pctChange": 0.03569638077469235
    },
    "coef": 0.11558686727582713,
    "avgCoef": -0.01970424341876154,
    "similar": {
        "HL": 0.46234746910330854,
        "INSM": 0.3572684988525566,
        "KGC": 0.3327500724607145,
        "AVTR": 0.27670795499364675
    }
}